



Press Release

Third Capital Markets Day – STADA commits to Russian market in Saint Petersburg

Bad Vilbel/Saint Petersburg, September 15, 2015 – For the third time, STADA Arzneimittel AG invited investors and analysts to a Capital Markets Day. This year, the focus of the event was on STADA's engagement in Russia. In St. Petersburg, the Executive Board and the Russian Management Board provided insights into the potentials and characteristics of the Russian market and highlighted the importance of Russia as a commercial location for STADA. After the event, Hartmut Retzlaff, Chairman of the Executive Board, concluded: "Despite all the challenges that we have been faced with in our market region CIS/Eastern Europe during the last few months, we continue to build on our business activities in Russia and are convinced of its long-term potential".

Helmut Kraft, Chief Financial Officer at STADA, added: "STADA is very well positioned with its convincing portfolio and a modern GMP production. In light of this, we expect to achieve double digit percentage growth in sales in local currency in the Russian market in financial year 2015 and, in the medium term, to emerge from the crisis as a strengthened company." At the event, Aleksey Alekhin, Deputy Director of Pharmaceutical and Medical Industry Development Department Russian Ministry for Industry and Trade, emphasized the attractiveness of the country in general and of the pharmaceutical sector for foreign investors in particular.

STADA's Senior Vice President Dmitry Efimov, who has been responsible for the market regions CIS/Eastern Europe since 2012 and is also the CEO of STADA's subsidiary Nizhpharm, then presented critical success factors in connection with the Russian umbrella label STADA CIS: "Not least thanks to our extraordinary sales network and a well-balanced product portfolio, we have become the number seven company in the Russian pharmaceutical market and the number two among local producers". Despite the economic situation, STADA CIS achieved convincing results in Russia in the first half of 2015: Compared with the overall

Members of the Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend



market in ruble, which increased by 11.1 percent as compared to the previous year, the sales of the Russian STADA subsidiary more than doubled with 23.4 percent.

STADA has been active in the Russian market for about ten years now. In financial year 2014, the Group achieved sales in Russia in the amount of Euro 360.7 million and employed 2,343 in the country.

All of the presentations shown at the Capital Markets Day are available on STADA's website under Investor Relations at www.stada.com/cmd2015.

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. STADA is represented in more than 30 countries with approximately 50 subsidiaries worldwide. Branded products such as Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2014, STADA achieved Group sales of Euro 2,062.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 431.9 million and adjusted net income of Euro 186.2 million. As of December 31, 2014, STADA employed 10,363 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-506 / E-mail: press@stada.de

Additional information for analysts:

STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail: communications@stada.de

Or visit us in the Internet at www.stada.com.

Members of the Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend